SILENCE THERAP. SP.ADR/1 Cash Flow Conversion Efficiency
SILENCE THERAP. SP.ADR/1 cash flow conversion efficiency. Based on the latest financial reports, SILENCE THERAP. SP.ADR/1 (XRP2) has a cash flow conversion efficiency ratio of -0.277x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.29 Million ≈ $-20.21 Million USD) by net assets (€62.30 Million ≈ $72.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SILENCE THERAP. SP.ADR/1 (2021–2025)
Cash flow conversion efficiency of SILENCE THERAP. SP.ADR/1 from 2021 to 2025. This chart illustrates how SILENCE THERAP. SP.ADR/1's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of SILENCE THERAP. SP.ADR/1 for real-time trading data and today's change.
SILENCE THERAP. SP.ADR/1 Cash Flow Conversion Ratio Explained
SILENCE THERAP. SP.ADR/1 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SILENCE THERAP. SP.ADR/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SILENCE THERAP. SP.ADR/1 ranked by their cash flow conversion efficiency. Also see SILENCE THERAP. SP.ADR/1 market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sichuan Tianwei Electronic Co Ltd
SHG:688511
|
-0.013x |
|
888 Holdings plc
F:C8V
|
-0.007x |
|
Air Asia Co Ltd
TW:2630
|
-0.006x |
|
J.G.CHEMICALS LIMITED
NSE:JGCHEM
|
0.066x |
|
Somany Ceramics Limited
NSE:SOMANYCERA
|
0.119x |
|
CSLM Digital Asset Acquisition Corp III, Ltd
NASDAQ:KOYN
|
-0.001x |
|
Kcc Glass Corp
KO:344820
|
-0.049x |
|
Journey Energy Inc
TO:JOY
|
0.053x |
Annual Cash Flow Conversion Efficiency for SILENCE THERAP. SP.ADR/1 (2021–2025)
The table below shows the annual cash flow conversion efficiency of SILENCE THERAP. SP.ADR/1 from 2021 to 2025. Review cash generation quality of SILENCE THERAP. SP.ADR/1 to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €62.30 Million ≈ $72.84 Million |
€-62.27 Million ≈ $-72.80 Million |
-0.999x | -98.04% |
| 2024-12-31 | €134.02 Million ≈ $156.69 Million |
€-67.64 Million ≈ $-79.08 Million |
-0.505x | +77.56% |
| 2023-12-31 | €21.99 Million ≈ $25.71 Million |
€-49.46 Million ≈ $-57.83 Million |
-2.249x | -5.31% |
| 2022-12-31 | €26.71 Million ≈ $31.23 Million |
€-57.04 Million ≈ $-66.69 Million |
-2.136x | -367.53% |
| 2021-12-31 | €11.51 Million ≈ $13.45 Million |
€9.19 Million ≈ $10.74 Million |
0.798x | -- |
About SILENCE THERAP. SP.ADR/1
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more